These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28522742)

  • 1. Evaluation of Radiopharmaceutical Adverse Reaction Reports to the British Nuclear Medicine Society from 2007 to 2016.
    Kennedy-Dixon TG; Gossell-Williams M; Cooper M; Trabelsi M; Vinjamuri S
    J Nucl Med; 2017 Dec; 58(12):2010-2012. PubMed ID: 28522742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database.
    Laroche ML; Quelven I; Mazère J; Merle L
    Ann Pharmacother; 2015 Jan; 49(1):39-47. PubMed ID: 25366341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full report on a survey of adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan.
    Matsuda H; Uehara T; Okazawa H; Mizumura S; Yokoyama K; Yoshimura M;
    Ann Nucl Med; 2020 Apr; 34(4):299-304. PubMed ID: 31989466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea.
    Sim DW; Park KH; Park HJ; Son YW; Lee SC; Park JW; Lee JH
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1279-1286. PubMed ID: 27364925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
    Silberstein EB; Ryan J
    J Nucl Med; 1996 Jan; 37(1):185-92. PubMed ID: 8543992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
    Silberstein EB
    J Nucl Med; 1998 Dec; 39(12):2190-2. PubMed ID: 9867168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011.
    Silberstein EB
    J Nucl Med; 2014 Aug; 55(8):1308-10. PubMed ID: 24876206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse drug reactions notified by pharmacovigilance in a tertiary care hospital in north India.
    Mittal N; Gupta M; Singla M
    Cutan Ocul Toxicol; 2014 Dec; 33(4):289-93. PubMed ID: 24517496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The 28th report on survey of the adverse reaction to radiopharmaceuticals (the 31st survey in 2005)].
    Kusakabe K; Arano Y; Okamura T; Kasagi K; Komatani A; Matsuda H; Maruno H; ; ;
    Kaku Igaku; 2007 Feb; 44(1):29-42. PubMed ID: 18240581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of adverse reactions to radiopharmaceuticals in Europe.
    Hesslewood SR; Keeling DH
    Eur J Nucl Med; 1997 Sep; 24(9):1179-82. PubMed ID: 9283115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospective survey on adverse effects of radiopharmaceuticals].
    Bagheri H; Galian ME; Bastie D; Couffignal AL; Tafani JA; Fourcade C; Morena I; Guiraud R; Montastruc JL
    Therapie; 1996; 51(5):550-3. PubMed ID: 9138391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The 33rd report on survey of the adverse reaction to radiopharmaceuticals (the 36th Survey in 2010)].
    Matsuda H; Arano Y; Okazawa H; Okamura T; Mizumura S; Yokoyama K; ; ;
    Kaku Igaku; 2012 Feb; 49(1):1-14. PubMed ID: 22624452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.
    Shalviri G; Yousefian S; Gholami K
    J Clin Pharm Ther; 2012 Aug; 37(4):448-51. PubMed ID: 22122488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system.
    Chen CJ; Cheng CF; Lin HY; Hung SP; Chen WC; Lin MS
    J Clin Pharm Ther; 2012 Dec; 37(6):647-51. PubMed ID: 22646235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The 35th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (the 38th Survey in 2012)].
    Matsuda H; Arano Y; Okazawa H; Mizumura S; Yokoyama K; Yoshimura M; ;
    Kaku Igaku; 2014 Feb; 51(1):1-12. PubMed ID: 24765821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The 41st Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 44th Survey in 2018)].
    ; Matsuda H; Uehara T; Okazawa H; Mizumura S; Yokoyama K; Yoshimura M
    Kaku Igaku; 2020; 57(1):11-21. PubMed ID: 32074551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A portable database of adverse reactions and drug interactions with radiopharmaceuticals.
    Gómez Perales JL; Martínez AA
    J Nucl Med Technol; 2013 Sep; 41(3):212-5. PubMed ID: 23857419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital.
    Khan LM; Al-Harthi SE; Saadah OI; Al-Amoudi AB; Sulaiman MI; Ibrahim IM
    Saudi Med J; 2012 Aug; 33(8):863-8. PubMed ID: 22886119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.